Harbin Pharmaceutical Group Co., Ltd. (600664.SS)
CNY 3.97
(0.0%)
CNY 3.97
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 15.33 Billion | 13.8 Billion | 12.8 Billion | 10.78 Billion | 11.82 Billion | 10.81 Billion |
| Cost of Revenue | 11.57 Billion | 10.4 Billion | 9.76 Billion | 8.44 Billion | 8.99 Billion | 7.86 Billion |
| Gross Profit | 3.76 Billion | 3.4 Billion | 3.03 Billion | 2.34 Billion | 2.83 Billion | 2.94 Billion |
| Operating Expenses | 3.39 Billion | 2.74 Billion | 2.44 Billion | 2.92 Billion | 2.58 Billion | 2.39 Billion |
| Selling, General and Administrative Expenses | 3.16 Billion | 1.89 Billion | 1.47 Billion | 1.3 Billion | 1.17 Billion | 945.62 Million |
| Research and Development Expenses | 120.67 Million | 115.8 Million | 97.73 Million | 92.52 Million | 125.14 Million | 137.26 Million |
| Other Expenses | 64.32 Million | 735.75 Million | 870.12 Million | 1.52 Billion | 1.27 Billion | 60.35 Million |
| Cost and Expenses | 14.79 Billion | 13.14 Billion | 12.21 Billion | 11.36 Billion | 11.57 Billion | 10.26 Billion |
| Operating Income | 659.62 Million | 695.8 Million | 642.41 Million | -577.69 Million | 602.83 Million | 527.37 Million |
| Interest Expense | 69.44 Million | 85.53 Million | 105.15 Million | 58.26 Million | 44.25 Million | 23.22 Million |
| Income Tax Expense | 176.32 Million | 190.06 Million | 220.68 Million | 76.6 Million | 185.18 Million | 184.09 Million |
| Earnings before Tax | 650.53 Million | 701.15 Million | 630.53 Million | -968.64 Million | 307.04 Million | 587.72 Million |
| Net Income | 395.26 Million | 465.15 Million | 371.08 Million | -1.04 Billion | 121.86 Million | 346.13 Million |
| Earnings Per Share Basic | 0.16 | 0.18 | 0.15 | -0.42 | 0.04 | 0.14 |
| Earnings Per Share Diluted | 0.16 | 0.18 | 0.15 | -0.42 | 0.04 | 0.14 |
| Weighted Average Shares Outstanding | 2.47 Billion | 2.51 Billion | 2.5 Billion | 2.5 Billion | 2.79 Billion | 2.47 Billion |
| Weighted Average Shares Outstanding (Diluted) | 2.47 Billion | 2.57 Billion | 2.5 Billion | 2.5 Billion | 2.79 Billion | 2.47 Billion |
| Gross Margin | 0.25 | 0.25 | 0.24 | 0.22 | 0.24 | 0.27 |
| EBIT Margin | 0.07 | 0.07 | 0.07 | -0.00 | 0.08 | 0.11 |
| Profit Margin | 0.03 | 0.03 | 0.03 | -0.10 | 0.01 | 0.03 |
| EBITDA | 1.02 Billion | 1.12 Billion | 1.06 Billion | -378.69 Million | 769.48 Million | 1.05 Billion |
| Earnings Before Tax Margin | 0.04 | 0.05 | 0.05 | -0.05 | 0.05 | 0.05 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 4.11 Billion | 3.96 Billion | 4.14 Billion | 3.92 Billion | 15.33 Billion | 3.79 Billion |
| Cost of Revenue | 3.03 Billion | 2.83 Billion | 2.96 Billion | 2.86 Billion | 11.57 Billion | 2.79 Billion |
| Gross Profit | 1.07 Billion | 1.13 Billion | 1.17 Billion | 1.06 Billion | 3.76 Billion | 996.08 Million |
| Operating Expenses | 820.88 Million | 920.64 Million | 926.09 Million | 907.21 Million | 3.15 Billion | 820.43 Million |
| Selling, General and Administrative Expenses | 1.32 Billion | 885.26 Million | 890.08 Million | 839.25 Million | - | 1.09 Billion |
| Research and Development Expenses | 27.68 Million | 25.37 Million | 25.26 Million | 35.74 Million | - | 20.16 Million |
| Other Expenses | -528.54 Million | -10 Million | -52.29 Thousand | -32.21 Million | -28.78 Million | -11.85 Million |
| Cost and Expenses | 3.85 Billion | 3.75 Billion | 3.89 Billion | 3.76 Billion | 14.72 Billion | 3.61 Billion |
| Operating Income | 245.59 Million | 213.34 Million | 245.13 Million | 161.07 Million | 614.13 Million | 171.39 Million |
| Interest Expense | 14.68 Million | 13.39 Million | 13.72 Million | 14.21 Million | 56.46 Million | 13.96 Million |
| Income Tax Expense | 56.57 Million | 51.59 Million | 54.77 Million | 47.2 Million | 176.32 Million | 44.25 Million |
| Earnings before Tax | 241.16 Million | 224.44 Million | 245.07 Million | 173.26 Million | 650.53 Million | 171.06 Million |
| Net Income | 164.9 Million | 166.64 Million | 176.74 Million | 104.76 Million | 395.26 Million | 107.78 Million |
| Earnings Per Share Basic | 0.07 | 0.07 | 0.07 | 0.04 | - | 0.04 |
| Earnings Per Share Diluted | 0.07 | 0.07 | 0.07 | 0.04 | - | 0.04 |
| Weighted Average Shares Outstanding | 2.51 Billion | 2.51 Billion | 2.52 Billion | 2.51 Billion | 2.47 Billion | 2.51 Billion |
| Weighted Average Shares Outstanding (Diluted) | 2.51 Billion | 2.51 Billion | 2.52 Billion | 2.51 Billion | 2.47 Billion | 2.51 Billion |
| Gross Margin | 0.26 | 0.29 | 0.28 | 0.27 | 0.25 | 0.26 |
| EBIT Margin | 0.06 | 0.07 | 0.06 | 0.06 | - | 0.05 |
| Profit Margin | 0.04 | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 |
| EBITDA | 255.84 Million | 287.94 Million | 260.91 Million | 237.17 Million | - | 189.57 Million |
| Earnings Before Tax Margin | 0.06 | 0.05 | 0.06 | 0.04 | 0.04 | 0.05 |
UPR
GENSOL
MPSYF
5532
278280
0ZC0